Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
NCT04970836Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2021
- Primary completion
- Dec 2027
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Open-label trial of recombinant hepatitis B vaccine Bio Farma in hepatitis B (HBV) (4 arms), sponsored by National Taiwan University Hospital. Primary endpoints: anti-HBs titer response rate and anti-HBs titer immune response change. Started Aug 2021; status: recruiting.
02
Drugs
recombinant hepatitis B vaccine Bio Farma
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04970836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970836.